Article Publish Status: FREE
Abstract Title:

Bioactive fraction fromleaves (DLBS3733) reduces fat droplet by inhibiting adipogenesis and lipogenesis.

Abstract Source:

J Exp Pharmacol. 2019 ;11:39-51. Epub 2019 May 2. PMID: 31118835

Abstract Author(s):

Agung Heru Karsono, Olivia Mayasari Tandrasasmita, Raymond Rubianto Tjandrawinata

Article Affiliation:

Agung Heru Karsono


Obesity has become a risk factor for metabolic diseases. One of the cellular characteristics of obesity is the occurrence of adipose cells hyperplasia.is a plant which has been used for the treatment of diabetes. Furthermore, some studies also indicated thatpossesses antiobesity activity. Its antiobesity activity was examined in the present study through adipogenesis, lipogenesis, and lipolysis pathways.DLBS3733, a bioactive fraction of, was explored for its potential benefits to alter obesity through adipogenesis and lipogenesis inhibition and lipolysis induction activity.This study was performed using 3T3-L1 cells. mRNA level and protein expressions related to adipogenesis, lipogenesis, and lipolysis pathways were assayed in this study.Antiadipogenic effects of DLBS3733 (15µg/mL) were found to be mediated by a significant downregulation of mRNA level of multicomponents involved in adipogenesis which include(CCAAT/enhancer-binding protein alpha) and(peroxisome proliferator-activated receptor gamma) by 75% and 80.1% (<0.05), respectively. DLBS3733 was found to inhibit lipogenesis, as shown by the significant reductions of adiponectin excretion and mRNA level of fatty acid synthase,(sterol regulatory element-binding protein), and(Acetyl-CoA carboxylase) by 44.7%, 70.9%, and 83.1%, respectively (<0.05). In addition, DLBS3733 was found to inhibit fat droplets accumulation in the cells in a dose-dependent manner through Oil-Red O staining. pAMPK protein was upregulated by 75% andwas downregulated by 88% (<0.05) which indicates the reduction of lipid synthesis. Meanwhile, DLBS3733 showed an insignificant effect on adipose triglyceride lipase, hormone-sensitive lipase, and carnitine palmitoyl-CoA transferase-1 which indicate that DLBS3733 does not induce lipolysis.These results demonstrate the inhibitory activity of DLBS3733 on adipogenesis and lipogenesis. DLBS3733 may provide an effective and potential benefit in the prevention of obesity.

Study Type : In Vitro Study
Additional Links
Pharmacological Actions : Hypolipidemic : CK(5358) : AC(1221)

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.